Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Operations (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Cash from Operations for 10 consecutive years, with 17422000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 36.5% year-over-year to 17422000.0, compared with a TTM value of 27674000.0 through Sep 2025, down 57.81%, and an annual FY2024 reading of 23444000.0, up 28.95% over the prior year.
  • Cash from Operations was 17422000.0 for Q3 2025 at Spero Therapeutics, up from 17693000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 44482000.0 in Q4 2022 and bottomed at 28223000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 6988947.37, with a median of 15479000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations surged 1763.01% in 2023, then crashed 167.4% in 2025.
  • Year by year, Cash from Operations stood at 27349000.0 in 2021, then skyrocketed by 262.65% to 44482000.0 in 2022, then crashed by 139.33% to 17493000.0 in 2023, then tumbled by 33.77% to 23401000.0 in 2024, then skyrocketed by 174.45% to 17422000.0 in 2025.
  • Business Quant data shows Cash from Operations for SPRO at 17422000.0 in Q3 2025, 17693000.0 in Q2 2025, and 4002000.0 in Q1 2025.